September 1st, 2026
Trail Biomed welcomes two new team members
We're pleased to announce that Ali Saadat and Steve Schöni have joined Trail Biomed. Ali Saadat, Ph.D., joins as an AI scientist and engineer, reinforcing our modeling capacity. Steve Schöni joins as CFO ad interim, outsourced by BDO, to mature our financial organization and to bring financial leadership and strategic oversight through our next phase of growth. Welcome to the team, Ali and Steve.
August 1st, 2026
New hire
Vlad Crișan, Ph.D joins as Head of Digital Biomedicine. Welcome to the team.
June 7th, 2026
Trail Biomed Awarded $4.9 Million Grant for AI-assisted vaccine engineering
Trail Biomed received a grant of over $4.9 million from the Gates Foundation to advance computational vaccine engineering. This funding will support the development of foundation models and infrastructure for vaccine design. The new technology integrates wet bench data generation with AI tools to create next-generation vaccine constructs better suited for preclinical development. This initiative represents a significant step toward accelerating vaccine deployment.
April 27th, 2026
Trail Biomed Announces Collaboration with the McDonnell Genome Institute at Washington University School of Medicine in St. Louis
Trail Biomed today announced a new collaboration with the McDonnell Genome Institute at Washington University School of Medicine in St. Louis. This collaboration aims to advance the analysis of multi-modal genomics data for the Alvin Goldfarb Neuronal Resiliency Center.
Dec 20th 2025
Trail Biomed Announces Collaboration with the Doherty Institute for Infection and Immunity and the Victorian Centre for Functional Genomics
Trail Biomed today announced a new collaboration with Professor Sammy Bedoui of the Doherty Institute for Infection and Immunity, Professor Kaylene J. Simpson of the Peter MacCallum Cancer Centre, Victorian Centre for Functional Genomics in Melbourne and Professor Malcolm McConville of the Institute of Molecular Science and Biotechnology, University of Melbourne This collaboration aims to advance the functional genomics of macrophage polarization by leveraging state-of-the-art high-throughput technologies and advanced data science approaches. Through this effort, Trail Biomed will enhance the annotation of chemical and metabolite libraries and establish a robust framework for data integration and interpretation, supporting deeper biological insights and translational discovery.
Nov 2025
Trail Biomed Publishes Whitepaper: “AI Co-Scientists for Drug Discovery”
We are excited to announce the release of our latest whitepaper, “AI Co-Scientists for Drug Discovery.” This in-depth report explores how next-generation AI agents are transforming preclinical drug R&D—accelerating hypothesis generation, experimental design, and data-driven decision-making. The whitepaper provides a clear overview of the current landscape, practical use cases, and the challenges and opportunities of integrating AI co-scientists into biomedical research. Discover how Trail Biomed’s approach combines domain-aware AI with rigorous scientific workflows to ensure transparency, reproducibility, and trust in drug development.
Read the full paper
May 15th, 2025
New publication in PNAS
Leah Soriaga and Amalio Telenti publish today work performed at Vir Biotechnology on the human host genetic landscape of The genetic underpinnings of respiratory viral infection. This is a landmark study of the network of genes supporting infection of 9 human respiratory viruses: influenza, parainfluenza virus, rhinovirus, RSV, common human coronavirus, MERS and SARS-CoV-2.
Read the full paper
May 1st, 2025
Trail Biomed Received a $2.65 Million Grant for Innovative Data Interoperability Framework
Trail Biomed is awarded a grant of over $2.65million from the Gates Foundation. Trail Biomed, a Swiss company founded by AmalioTelenti, aims at advancing global health through innovative therapeutics. This funding will support the development of a working framework for data interoperability and validation, integrating wet bench data generation with AI tools to create novel, cost-effective small molecule therapies to improve public health.This initiative represents a significant step toward addressing critical gaps in data integration and fostering rapid testing and validation of drug leads. For more information, visit trail biomed.